Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Efficacy of injecting platelet concentrate combined with hyaluronic acid for the treatment of vulvovaginal atrophy in postmenopausal women with history of breast cancer

a phase 2 pilot study

Hersant, Barbara MD1,2; SidAhmed-Mezi, Mounia PhD1; Belkacemi, Yazid MD, PhD2,3; Darmon, Franklin MD1; Bastuji-Garin, Sylvie MD, PhD4; Werkoff, Gabrielle MD2,5; Bosc, Romain MD1,2; Niddam, Jeremy MD1; Hermeziu, Oana MD1; La Padula, Simone MD1; Meningaud, Jean Paul MD, PhD1

doi: 10.1097/GME.0000000000001122
Original Articles

Objective: Approximately 50% to 70% of breast cancer survivors are affected by one or more symptoms of vulvovaginal atrophy (VVA). For those who cannot take hormone therapy, autologous platelet-rich plasma combined with hyaluronic acid (A-PRP-HA) may provide a new alternative therapy for the treatment of VVA in postmenopausal women with history of breast cancer.

Methods: We enrolled 20 postmenopausal breast cancers survivors with VVA and a score of <15 on the Gloria Bachman Vaginal Health Index (VHI) comprised of five items including: vaginal pH, elasticity, fluid volume (secretions), epithelial integrity, and moisture.

We administered intramucosal injections of A-PRP combined with HA (Regenkit) and performed clinical evaluations at 0, 1, 3, and 6 months. Primary endpoint: evaluation of vulvovaginal mucosa changes using the VHI; secondary endpoint: evaluation of dyspareunia and sexual dysfunction based on the Female Sexual Distress (FSD) score.

Results: All participants (20 women) showed improvement in the clinical symptoms of vaginal dryness and dyspareunia. The VHI score showed a significant increase at 6 months, going from a total baseline score (pretreatment) of 10.7 ± 2.12 to 20.75 ± 4.8 (P < 0.0001) at 6 months. Improvement in hydration and vaginal epithelial integrity was reported. A VHI score of > 15 showed a successful treatment outcome. The FSD score decreased significantly during the study, from a baseline score of 36.35 ± 2.53 pretreatment to 30.15 ± 2.47 6 months after treatment, representing improvement of 17% (P < 0.0001, respectively). No adverse events were reported.

Conclusions: The injection of A-PRP-HA appeared to be a promising method to improve the trophicity and hydration of vaginal mucosa for the treatment of VVA in postmenopausal breast cancer survivors with contraindications to hormone therapy.

1Department of Maxillofacial and Plastic & Reconstructive Surgery, Henri Mondor University Hospital, Créteil, France

2Henri Mondor Breast Center, Henri Mondor Hospital, Creteil, France

3Department of Radiation Oncology, University of Paris East Créteil (UPEC), INSERM U955 EQ 07, Créteil, France

4AP-HP, Hospital Henri Mondor, Department of Public Health and Clinical Research Unit (URC Mondor), Créteil cedex, France

5Department of Gynecology, Bégin Military Teaching Hospital, Saint Mandé, France.

Address correspondence to: Barbara Hersant, MD, Department of Maxillofacial and Plastic & Reconstructive Surgery, Henri Mondor Hospital, 51 avenue du Maréchal de Lattre de Tassigny, Créteil 94010, France. E-mail:

Received 17 November, 2017

Revised 21 March, 2018

Accepted 21 March, 2018

Funding/support: None reported.

Financial disclosure/conflicts of interest: MSA-M obtained a grant from RegenLab to conduct her research. The other authors declare that they have no conflicts of interest.

© 2018 by The North American Menopause Society.